logo
logo
Sign in

Flu Season Alert: A Look into Influenza Diagnostics Market

avatar
Ayush Das
Flu Season Alert: A Look into Influenza Diagnostics Market

Influenza Diagnostics Market size was valued at USD 1.07 billion in 2021 and is poised to grow from USD 1.1 billion in 2022 to USD 1.46 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).

 

 

Influenza is simply referred to as the flu. It is an infectious disease of the upper respiratory tract caused by the influenza virus. The seasonal influenza virus is classified into three types: Influenza B, Influenza A, And Influenza C, which are characterized by two major surface proteins: hemagglutinin (HA) and neuraminidase (NA). Different serotypes are observed as a result of differences in these surface proteins, which determine the antibody response to the viruses. Because influenza is a highly contagious and communicable disease, infected patients who serve as carriers of the disease can easily transmit the disease in public places.

 

The disease burden varies by region, with temperate climate regions experiencing seasonal influenza outbreaks. In tropical regions where influenza occurs all year, causing constant outbreaks, disease management and treatment are difficult. Rising demand for rapid disease diagnosis, rising influenza prevalence, and increased influenza research for diagnostic technologies are driving the Influenza Diagnostics Market growth.

 


 Global Influenza Diagnostics Market Size, Share & Industry Analysis, Report [2030] Competitive Landscape

The Global Influenza Diagnostics Market is segmented based on Test Type, End-User, and Region. Based on Test Type it is categorized into Traditional Diagnostic Test and Molecular Diagnostic Assay. The Traditional Diagnostic Test segment is further bifurcated into RIDT, Viral Culture, Direct Fluorescent Antibody (DFA) Test, and Serological Assay. Molecular Diagnostic Assay is sub-segmented into RT-PCR, Nucleic Acid Sequence-based Amplification (NASBA) Test, Loop-mediated Isothermal Amplification-based Assay (LAMP), Simple Amplification-based Assay (SAMBA), and Other Molecular Diagnostic Assays. By End User, the Influenza Diagnostics Market studied is segmented into hospitals, Laboratories, and Other End Users. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Influenza Diagnostics Market Analysis by Test Type

In 2022, the rapid influenza diagnostic test (RIDT) is anticipated to hold the largest market share in the test type segment of the influenza diagnostics market, out of all traditional diagnostic tests. Rapid influenza diagnostic tests (RIDTs) are immunoassays that detect and provide qualitative results for influenza A and B viral nucleoprotein antigens in respiratory specimens. It is capable of diagnosing patients with influenza-like illness, particularly if performed within the first four days of symptoms appearing. RIDT's popularity is driven by the benefits of faster results and ease of use. Some RIDTs are also approved for use in the office or at the patient's bedside. The RIDT segment is also expected to grow rapidly due to its widespread use in point-of-care settings.

Influenza Diagnostics Market Analysis by End-user

The diagnostic laboratories segment dominated the influenza diagnostics market in 2021. The rising prevalence of influenza, as well as the growing demand for rapid disease diagnosis, are driving the growth of this segment

 

 

Read more: https://www.skyquestt.com/report/influenza-diagnostics-market

 

collect
0
avatar
Ayush Das
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more